MNG1254
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.347
- MYC_TARGETS_V2+0.346
- TGF_BETA_SIGNALING+0.329
- MYOGENESIS+0.324
- UV_RESPONSE_UP+0.299
- APICAL_JUNCTION+0.213
- XENOBIOTIC_METABOLISM+0.173
- APICAL_SURFACE+0.146
- INTERFERON_ALPHA_RESPONSE+0.142
- NOTCH_SIGNALING+0.140
Top 10 suppressed
- E2F_TARGETS-0.385
- G2M_CHECKPOINT-0.352
- PROTEIN_SECRETION-0.346
- OXIDATIVE_PHOSPHORYLATION-0.340
- MYC_TARGETS_V1-0.264
- MTORC1_SIGNALING-0.232
- SPERMATOGENESIS-0.202
- GLYCOLYSIS-0.201
- PEROXISOME-0.181
- BILE_ACID_METABOLISM-0.163
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 63229_S123 | — | cohortA1 | 0.741 |
| 2 | SRR23303772 | — | — | 0.716 |
| 3 | MNG720 | — | — | 0.712 |
| 4 | MNG399 | — | — | 0.709 |
| 5 | SRR4195649 | — | — | 0.702 |
| 6 | SJEPD001501_D1.RNA-Seq | EPN | Supratentorial EPN | 0.686 |
| 7 | DRR168571 | — | — | 0.681 |
| 8 | BS_JFR750KD | low-grade glioma | — | 0.674 |
| 9 | R109 | — | — | 0.656 |
| 10 | MDT-AP-1201 | Med | Medulloblastoma | 0.655 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.347 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.346 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.329 | Inavolisib | — uncovered |
| MYOGENESIS | 0.324 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.299 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.213 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.173 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.146 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.142 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.131 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.126 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.118 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.118 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.115 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.099 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.097 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.093 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.047 | Idelalisib | — uncovered |